Crossmark

Improved ex vivo fluorescence imaging of human head and neck cancer using the peptide tracer TPP-IRDye800 targeting membrane-bound Hsp70 on tumor cells

Crossref DOI link: https://doi.org/10.1038/s41416-024-02872-8

Published Online: 2024-10-15

Published Print: 2024-12-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Holzmann, Katharina L. K. https://orcid.org/0009-0008-3612-7237
Wolf, Johanna L.

Stangl, Stefan

Lennartz, Philipp

Kasajima, Atsuko

Mogler, Carolin

Haller, Bernhard

Ebert, Eva-Vanessa

Jira, Daniel

Lauterbach, Maren L. A.

von Meyer, Franziska

Stark, Leonhard

Mauch, Leonie

Schmidl, Benedikt

Wollenberg, Barbara

Multhoff, Gabriele

Wirth, Markus
License Information

Text and Data Mining valid from 2024-10-15

Version of Record valid from 2024-10-15
More Information

Article History

Received: 27 May 2024

Revised: 11 September 2024

Accepted: 30 September 2024

First Online: 15 October 2024

Competing interests

: GM has ownership interest as a patent inventor (PCT/EP2015/063697) and is CSO of multimmune GmbH, Munich, Germany providing the cmHsp70.1 mAb.

: All patients gave their written consent to image their excised tissue and to provide blood and tumor biopsies. The study protocol was approved by the Ethics Committee of the Klinikum rechts der Isar (MRI) of the Technical University of Munich (2021-132). All analyses were conducted in accordance with the Declaration of Helsinki.

Document is current

Any future updates will be listed below